A new child-friendly malaria drug, which will be distributed in Africa, where a child dies every 30 seconds from malaria, i s to be launched in the UK. The new drug is the result of public-private collaboration between Medicines for Malaria Venture (MMV), a non-profit organization funded by the UK's Department for International Development, and the dmg company Novaros.
news www.pharma-mag.com Atlas Strengthens NSCLC Treatments Bio-Rad’s Antibody Binding Affinities Genentech has seen a Phase III study (ATLAS) of Tarceva (erlotinib) in Bio-Rad Laboratories is to collaborate with Integral Molecular, Inc. to offer the first combination with Avastin (bevacizumab) as a maintenance therapy following system for rapidly and reproducibly characterizing the binding affinities of antibodies initial treatment with Avastin plus chemotherapy in advanced NSCLC (non- to diverse integral membrane proteins, including GPCRs and ion channels. Integral Molecular, a solution provider for scientific research and drug discovery applications small cell lung cancer) meet its primary endpoint. The study was stopped involving integral membrane proteins, has developed a technology, the Lipoparticle, that early on the recommendation of an independent data safety monitoring board enables integral membrane protein interactions to be measured using Bio-Rad’s label- after a preplanned interim analysis showed that combining Tarceva with free, high throughput ProteOn XPR36 Protein Interaction Array System. Avastin significantly extended the time that patients lived without their disease Understanding antibody binding characteristics is critical for the screening of advancing, as defined by PFS (progression-free survival), compared with Avastin new drug candidates and developing reagents that achieve optimal pharmacological plus a placebo. A preliminary safety analysis showed adverse events were characteristics. Current methods for measuring the binding affinity of ligands to consistent with previous Avastin or Tarceva studies, as well as trials evaluating transmembrane proteins require the use of whole cells or cell membrane preparations, the two medicines together, and no new safety signals were observed. which are heterogeneous and too impure to generate high quality, reproducible “This is the second study to show that people with lung cancer who biosensor data. The challenges with these methods have thus far constrained the study took the daily Tarceva pill following initial treatment lived longer without of ligand binding strengths to a limited number of integral membrane proteins. Integral their cancer getting worse. We plan to discuss these data with the FDA Molecular’s proprietary Lipoparticle technology offers scientists working with membrane- bound targets a standardized reagent with higher concentrations of membrane proteins to determine next steps,” said Hal Barron, MD, Genentech’s Senior VP, than cell membrane preparations. Development and Chief Medical Officer.” Tumours use different pathways to grow and these results showed that combining medicines targeting two of New Web for Valois these pathways — instead of one — delayed disease progression.” An earlier Valois Pharma’s new web site is now on-line at www.valoispharma.com. At- study, SATURN, showed that Tarceva delayed disease progression when tractive and easy-to-use, this site provides both the pharmaceutical industry given as a single agent immediately following treatment with chemotherapy, and the global scientific community with free access to highly- relevant compared with a placebo. In ATLAS, patients were initially treated with Avastin information and tools. plus chemotherapy followed by the addition of Tarceva to Avastin in the Scientific publications to support advances in research Valois Pharma has been developing and globally promoting research, new technology and maintenance phase. knowledge about nasal and pulmonary drug delivery devices over the past
Pages to are hidden for
"Nice-Tasting Malaria Drug!"Please download to view full document